Media

AYOXXA develops multiplex assay for stratification of sepsis patients using soluble biomarkers

Cologne, Germany, September 25, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company’s innovative bead-based protein analysis platform LUNARIS™.

AYOXXA launches LUNARIS Mouse 12-Plex Th17 Kit to elucidate Th17 cell biology

Cologne, Germany, September 18, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, focused on the development of innovative multiplex protein analysis technologies enabling translational research in basic and clinical research, today announced the expansion of its catalogue of immunoassays for multiplex protein analysis with the introduction of LUNARIS™ Mouse 12-Plex Th17 Kit for the quantitative analysis of soluble mouse T helper 17 (Th17) cell-related markers. The assay is optimized for usage on LUNARIS™, AYOXXA’s innovative multiplex protein analysis system.

AYOXXA introduces LUNARIS™, its advanced fully integrated low-volume beads-on-a-chip multiplex protein analysis system

Cologne, Germany, September 11, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, today announces the introduction of its advanced low-volume beads-on-a-chip multiplex protein analysis system. The LUNARIS™ system can be readily integrated into any laboratory routine and is optimized to provide easy-to-use, standardized workflow from sample to result.

AYOXXA at Sachs 17th Annual Biotech in Europe Forum

Rodney Turner, CEO of AYOXXA is scheduled to talk about recent and further developments of the Company and will participate in the panel discussion on Diagnostics & Imaging.

This year, Sachs Forum for Global Partnering & Investment will take place in
Basel, Congress Center, Switzerland.
 

Media Response

>

In the following section, we consolidate articles published about AYOXXA as a service.
They are linked to sources in either online or offline media and therefore are written in German or English language as indicated.

Enjoy Reading!

07.11. 2016

Global Pharma Update

AYOXXA Biosystem announced changes in management team

The supervisory board of AYOXXA Biosystems GmbH announces that Mr. Rodney Turner has assumed duties as the interim CEO of AYOXXA effective October 15, 2016. Mr. Turner is pleased to lead the company as its orientation shifts toward market development and product refinement. The supervisory board and the management team wish to thank Dr. Andreas Schmidt for his years of leadership in founding and establishing AYOXXA as a leading biotech start-up in Germany. Dr. Schmidt has stepped down from his position as CEO, though he will remain associated with the company. Mr. Turner and Dr. Markus Zumbansen (CTO) were formally registered as managing directors of the company effective October 15, 2016.

16.06. 2016

CELL

A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain Inflammation

CELL Volume 165 (7): 1672-1685 "A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation"
Peer reviewed scientific publication by Maninjay K. Atianand et al.

more

Corresponding author:
Katherine A. Fitzgerald, PhD
Program in Innate Immunity; Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA Link to website

02.06. 2016

Bonner General Anzeiger

Ausländische Investoren suchen deutsche Start-ups

High-Tech Gründerfonds bringt in Bonn Geldgeber und Unternehmer zusammen. Seit 2005 hat der Fonds in mehr als 400 Unternehmen aus der High-Tech-Branche investiert.

Molekularbiologe Andreas Schmidt hat den Weg geschafft: Heraus aus dem Forschungslabor hinein in die freie Wirtschaft. Vor gut sechs Jahren gründete er mit einem Partner in Köln die Firma Ayoxxa. Mittlerweile ist das junge Biotechnologie-Unternehmen auch mit Standorten in Singapur und in den USA vertreten. Die Kölner haben eine Technologie entwickelt, die es ermöglicht, unterschiedliche Proteine simultan zu analysieren. Diese neuartigen Biochips finden Anwendung in pharmakologischen Tests und in der biomedizinischen Forschung.

LINK zur  HTGF Webseite